-
EP4304713
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4304713
| EP4304713 - HETEROCYCLIC RIP1 KINASE INHIBITORS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 15.12.2023 Database last updated on 02.08.2024 | |
| Former | The international publication has been made Status updated on 16.09.2022 | ||
| Former | unknown Status updated on 13.04.2022 | Most recent event Tooltip | 17.05.2024 | Change: Validation states | published on 19.06.2024 [2024/25] | Applicant(s) | For all designated states Rigel Pharmaceuticals, Inc. 611 Gateway Boulevard Suite 900 South San Francisco, CA 94080 / US | [2024/03] | Inventor(s) | 01 /
BHAMIDIPATI, Somasekhar South San Francisco, California 94080 / US | 02 /
DEFREES, Kyle South San Francisco, California 94080 / US | 03 /
SHAW, Simon South San Francisco, California 94080 / US | 04 /
TAYLOR, Vanessa South San Francisco, California 94080 / US | [2024/03] | Representative(s) | Faggiani, Davide, et al Eli Lilly and Company Limited European Patent Operations 8 Arlington Square West Downshire Way Bracknell RG12 1PU / GB | [2024/03] | Application number, filing date | 22714650.3 | 10.03.2022 | [2024/03] | WO2022US19744 | Priority number, date | US202163159970P | 11.03.2021 Original published format: US 202163159970 P | [2024/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022192533 | Date: | 15.09.2022 | Language: | EN | [2022/37] | Type: | A1 Application with search report | No.: | EP4304713 | Date: | 17.01.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 15.09.2022 takes the place of the publication of the European patent application. | [2024/03] | Search report(s) | International search report - published on: | EP | 15.09.2022 | Classification | IPC: | A61P5/00, A61P11/00, A61P17/00, A61P19/00, A61P35/00, A61P37/00, C07D401/14, C07D413/14, C07D417/14, A61K31/553, A61K31/55 | [2024/03] | CPC: |
C07D417/14 (EP,IL,KR);
C07D413/14 (EP,IL,KR,US);
A61K31/553 (IL,KR,US);
A61K31/55 (IL,KR,US);
A61P11/00 (EP,IL);
A61P17/00 (EP,IL,KR);
A61P19/00 (EP,IL);
A61P19/02 (KR);
A61P29/00 (KR);
A61P35/00 (EP,IL);
A61P37/00 (EP,IL,KR);
A61P43/00 (KR);
A61P5/00 (EP,IL);
C07D401/14 (EP,IL,KR,US);
C07D405/14 (IL,KR,US);
C07D413/12 (KR)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/03] | Extension states | BA | 11.10.2023 | ME | 11.10.2023 | Validation states | MA | 11.10.2023 | MD | 11.10.2023 | TN | 11.10.2023 | Title | German: | HETEROCYCLISCHE RIP1-KINASEHEMMER | [2024/03] | English: | HETEROCYCLIC RIP1 KINASE INHIBITORS | [2024/03] | French: | INHIBITEURS HÉTÉROCYCLIQUES DE LA RIP1 KINASE | [2024/03] | Entry into regional phase | 11.10.2023 | National basic fee paid | 11.10.2023 | Designation fee(s) paid | 11.10.2023 | Examination fee paid | Examination procedure | 10.10.2023 | Amendment by applicant (claims and/or description) | 11.10.2023 | Examination requested [2024/03] | 11.10.2023 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 31.03.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]WO2014125444 (GLAXOSMITHKLINE IP DEV LTD [GB]); | [XI]WO2016027253 (GLAXOSMITHKLINE IP DEV LTD [GB]); | [I]WO2017004500 (GENENTECH INC [US], et al); | [I]WO2017136727 (DENALI THERAPEUTICS INC [US]); | [I]WO2020088194 (SHANGHAI INST MATERIA MEDICA CAS [CN]); | [XP]WO2021046447 (RIGEL PHARMACEUTICALS INC [US], et al) | by applicant | US4738851 | US4882150 | US4921475 | US5008110 | US5077033 | US5087240 | US5088977 | US5112596 | US5164189 | US5163899 | US5254346 | US5268164 | US5290561 | US5332213 | US5336168 | US5352456 | US5403841 | US5407713 | US5506206 | US5521222 | US5686416 | US5698219 | US5776445 | US5800807 | US6056950 | US6197934 | US6261547 |